Tuesday, September 27, 2022

Latest Posts

Leuko Raises $5 Million in Collection A

BOSTON–(BUSINESS WIRE)–Leuko, an MIT startup growing PointCheck, the primary resolution that permits at-home noninvasive white blood cell monitoring, as we speak introduced a primary closing of $5 million for his or her Collection A spherical. The brand new funding, from HTH VC, Good Development Capital, IAG Capital Companions, Nina Capital, and angel buyers, will speed up Leuko’s scientific trials to acquire regulatory approval in collaboration with main most cancers facilities, together with Boston Medical Heart and MD Anderson within the USA, and Dexeus and Hospital 12 de Octubre in Europe. Leuko can even proceed to pursue its go-to-market and partnership actions with healthcare suppliers, medical system distributors and pharmaceutical firms. 

“Low WBC ranges is likely one of the most typical in addition to most devastating and costliest uncomfortable side effects of most cancers chemotherapy. Scientific knowledge signifies that as many as one out of each six chemotherapy sufferers undergo life-threatening infections and hospital readmissions straight linked to low WBCs,” stated Leuko co-founder and CEO Dr. Carlos Castro-Gonzalez. “At Leuko, we’re engaged on an answer to assist sufferers and suppliers stop these hospital readmissions and enhance scientific outcomes, by remotely monitoring WBC ranges earlier than infections ensue.”

With Leuko, sufferers merely place their finger onto an web related PointCheckTM system for simply 1 minute a day. The system measures WBC ranges with no blood pattern draw. The information is shipped to the affected person’s care workforce, which might triage findings to assist sufferers obtain applicable, preventive remedies underneath the course of their clinician. The expertise has demonstrated glorious diagnostic accuracy and dwelling usability in current peer-reviewed research.

Related:  Over 20,000 Startup Staff Lose Jobs Globally, India and US Prime Checklist

“We’re excited to help Leuko as they scale and produce this clinically validated resolution to the tens of millions of sufferers who can stay more healthy lives by means of an elevated monitoring of their weakened immune system,” stated Michele Gaiotto, CEO of HTH VC, who leads the Firm Collection A. “We imagine that Leuko is constructing a robust workforce and expertise platform and are honored to help its worthy mission.”

Amy Salzhauer, Managing Companion of Good Development Capital, who led the Firm Collection Seed, stated “We proceed to be impressed by the potential worth delivered by the PointCheckTM platform, which has been achieved by integrating proprietary distant monitoring expertise in a product that can be utilized by unsupervised sufferers at dwelling.”

About Leuko

Leuko is a startup spun out from MIT and the Madrid M+Imaginative and prescient Consortium and based by Carlos Castro-Gonzalez, Ian Butterworth, Aurelien Bourquard, and Alvaro Sanchez-Ferro. They’re growing a platform expertise, PointCheckTM, that mixes optics and AI to make noninvasive blood testing simpler, quicker and extra accessible than state-of-the artwork options. For its first utility, Leuko goals to enhance scientific outcomes for >2M most cancers chemotherapy sufferers a yr, scale back their chemotherapy-related hospital readmissions by 50% and save >$6B yearly in healthcare value. For extra info, go to https://leuko.com/ or comply with us on Twitter @leuko.

About HTH VC

HTH is a full-fledged funding and advisory firm investing alongside shiny innovators devoted to bettering people’ well being. Born in 2020, HTH enhances ZCube-Zambon Analysis Enterprise scouting and investing actions with direct participation in early-stage deep tech startups devoted to bettering human lives. hthvc.com

Related:  How Byju's Losses Rose To Rs 4,500 Crores In Delayed FY21 Outcomes?

About Good Development Capital

Good Development Capital is a majority ladies and minority-managed early-stage enterprise capital agency that funds transformative start-ups in sectors together with biomed tech, inexperienced tech and knowledge sciences. Good Development Capital and its funds meet each ESG and UNSDG affect targets. goodgrowthvc.com

Latest Posts

Don't Miss

Stay in touch

To be updated with all the latest news, offers and special announcements.